BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12521996)

  • 1. Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells.
    Liu Q; Gazitt Y
    Blood; 2003 May; 101(10):4105-14. PubMed ID: 12521996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.
    Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC
    Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines.
    Liu Q; El-Deiry WS; Gazitt Y
    Exp Hematol; 2001 Aug; 29(8):962-70. PubMed ID: 11495702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.
    Gazitt Y; Rothenberg ML; Hilsenbeck SG; Fey V; Thomas C; Montegomrey W
    Int J Oncol; 1998 Oct; 13(4):839-48. PubMed ID: 9735415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
    Derenne S; Monia B; Dean NM; Taylor JK; Rapp MJ; Harousseau JL; Bataille R; Amiot M
    Blood; 2002 Jul; 100(1):194-9. PubMed ID: 12070027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
    Gazitt Y; Fey V; Thomas C; Alvarez R
    Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated delivery of p53 results in substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34(+) hematopoietic progenitor cells and normal lymphocytes.
    Liu Q; Gazitt Y
    Exp Hematol; 2000 Dec; 28(12):1354-62. PubMed ID: 11146157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.
    Feinman R; Koury J; Thames M; Barlogie B; Epstein J; Siegel DS
    Blood; 1999 May; 93(9):3044-52. PubMed ID: 10216101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
    Liu Q; Hilsenbeck S; Gazitt Y
    Blood; 2003 May; 101(10):4078-87. PubMed ID: 12531793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells.
    Tosi P; Pellacani A; Visani G; Ottaviani E; Ronconi S; Zamagni E; Benni M; Cavo M; Tura S
    Eur J Haematol; 1999 Mar; 62(3):143-8. PubMed ID: 10089890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.
    Rowley M; Liu P; Van Ness B
    Blood; 2000 Nov; 96(9):3175-80. PubMed ID: 11050000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxol can induce phosphorylation of BCL-2 in multiple myeloma cells and potentiate dexamethasone-induced apoptosis.
    Kroning R; Lichtenstein A
    Leuk Res; 1998 Mar; 22(3):275-86. PubMed ID: 9619919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.
    Jazirehi AR; Bonavida B
    Mol Cancer Ther; 2004 Jan; 3(1):71-84. PubMed ID: 14749477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of p53, bcl-2 and bax network in dexamethasone induced apoptosis in multiple myeloma cell lines.
    Tian E; Gazitt Y
    Int J Oncol; 1996 Apr; 8(4):719-26. PubMed ID: 21544419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.
    Avramis VI; Nandy P; Kwock R; Solorzano MM; Mukherjee SK; Danenberg P; Cohen LJ
    Anticancer Res; 1998; 18(4A):2327-38. PubMed ID: 9703875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: a study with cell lines overexpressing bcl-2 and with bcl-2 transfected cell lines.
    Gazitt Y; Hu WX
    Int J Oncol; 1998 Jan; 12(1):211-20. PubMed ID: 9454907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoids protect against apoptosis induced by serum deprivation, cyclic adenosine 3',5'-monophosphate and p53 activation in immortalized human granulosa cells: involvement of Bcl-2.
    Sasson R; Tajima K; Amsterdam A
    Endocrinology; 2001 Feb; 142(2):802-11. PubMed ID: 11159853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
    Pei XY; Dai Y; Grant S
    Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.